Myricx Bio

Myricx is headquartered in London and focused on discovering and developing a completely novel class of payloads for antibody drug conjugates (ADCs), based on inhibitors of the enzymes, N-myristoyltransferases (NMT) for the treatment of cancer.

Myricx is progressing a pipeline of proprietary differentiated ADCs based on our novel N-myristoyltransferase inhibitor (NMTi) payload chemistry platform to address serious unmet needs in oncology.

Based on compelling preclinical efficacy and safety data across multiple solid tumour-associated antigens and cancer cell types are prioritising two proprietary, differentiated NMTi-ADCs that target the cancer associated antigens – B7-H3 and HER2.

Brandon Capital is aware of scammers impersonating us - offering jobs and asking for bank details. We do not offer employment or ask for banking details via SMS, websites or phone calls. Do not provide any details and report to the relevant authorities in your location.